Clinical Research Directory
Browse clinical research sites, groups, and studies.
Berberine Improving Cognitive Impairments in Schizophrenia
Sponsor: Tianjin Anding Hospital
Summary
The study was a 12-week, randomized, double-blind, placebo-controlled trial. Berberine (300 mg, three times a day) has been used as an auxiliary treatment on the basis of stable antipsychotic treatment. All participants were randomly divided into two groups.Any stable antipsychotic + berberine(BBR) or any stable antipsychotic +placebo. Positive and Negative Syndrome Scale (PANSS) has been used for psychiatric symptoms. MATRICS Consensus Cognitive Battery(MCCB)has been used for cognitive symptoms. The treatment Emergent Symptom Scale(TESS) has been used for evaluate adverse effects. Plasma Metabolomics, Inflammatory Factors, BDNF, fecal Macrogene Sequencing, and fecal Metabolomics were obtained at 0, 4,8 ,12weeks.
Official title: Study on the Mechanism s of Berberine Improving Cognitive Impairments in Schizophrenia Based on "Gut m Icrobiota-gut-brain"Axis
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2023-07-21
Completion Date
2028-07-30
Last Updated
2026-01-22
Healthy Volunteers
No
Conditions
Interventions
Berberine
Berberine 300mg#three times a day# plus any stable antipsychotic drug
Placebo
The placebo were matched to Berberine in shape, smell and colour and tablets were sealed in identical bottles
Locations (1)
Tianjin Anding Hospital
Tianjin, China